Roivant Sciences Ltd. (ROIV) insider trading

By person

15 insiders · 122 transactions

929×

Matthew Gline holds 929 times base salary in stock. $673.89M of shares against $725.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Matthew Gline last reported holding, valued at $40.45, the price Common Shares was last bought or sold at on the open market here, on 15 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

MANCHESTER KEITH S

Director

—

$154.47M (20)

−$154.47M

15,442,623

2.14%

$624.65M

−60.6%

Gold Daniel Allen

Director

—

$147.38M (19)

−$147.38M

22,654,981

3.14%

$916.39M

−67.4%

QVT Financial LP entity

Director by Deputization

—

$147.38M (19)

−$147.38M

13,689,166

1.90%

$553.73M

−76.0%

Sukhatme Mayukh

President & CIO

—

$109.13M (13) scheduled

−$109.13M

18,630,739

2.58%

$753.61M

−17.2%

Ramaswamy Vivek

10% owner

—

$105.88M (6) scheduled

−$105.88M

47,011,612

6.51%

$1.90B

−12.0%

Venker Eric

President & Immunovant CEO

—

$105.07M (25) scheduled

−$105.07M

1,599,154

0.2214%

$64.69M

+154.5%

Torti Frank

President and Vant Chair

—

$82.04M (3) scheduled

−$82.04M

13,536,202

1.87%

$547.54M

—

Gline Matthew

CEO

—

$46.17M (4) scheduled

−$46.17M

16,659,945

2.31%

$673.89M

−9.0%

Pulik Richard

CFO

—

$9.12M (2) scheduled

−$9.12M

271,810

0.0376%

$10.99M

−5.2%

Fitzgerald Meghan

Director

—

$3.27M (5) scheduled

−$3.27M

41,162

0.0057%

$1.67M

+40.1%

Epperly Melissa B,

Director

—

$2.01M (5)

−$2.01M

14,954

0.0021%

$604.89K

−58.9%

Humes Jennifer

Chief Accounting Officer

—

$384.07K (1)

−$384.07K

109,782

0.0152%

$4.44M

—

Kumar Rakhi

Chief Accounting Officer

—

162,306

0.0225%

$6.57M

−22.5%

Oren Ilan

Director

—

123,680

0.0171%

$5.00M

+29.4%

MOMTAZEE JAMES C

Director

—

111,959

0.0155%

$4.53M

+21.1%

Individual transactions

Insider

Date

Role

Action

Price

Amount

Fitzgerald Meghan

15 Sep 2026

Director

Sold on a plan

400

$40.45

$16.18K

Fitzgerald Meghan

15 Sep 2026

Director

Sold on a plan

4,712

$39.68

$186.97K

Epperly Melissa B,

15 Sep 2026

Director

Sold on a plan

600

$40.38

$24.23K

Epperly Melissa B,

15 Sep 2026

Director

Sold on a plan

4,338

$39.65

$172.00K

Venker Eric

23 Sep 2025

President & Immunovant CEO

Sold on a plan

611,000

$14.83

$9.06M

Show all 122 transactions →

Roivant Sciences Ltd.

By person

Individual transactions

What was left out